CAMP4 Therapeutics granted stock options to four new employees as part of their employment inducement strategy.
Quiver AI Summary
CAMP4 Therapeutics Corporation has announced the granting of non-qualified stock options to four new employees, totaling 92,000 shares, as an inducement for their employment. This decision was made on December 11, 2025, in compliance with Nasdaq Listing Rule 5635(c)(4). The options, which have a ten-year term and an exercise price of $6.01 per share, will vest over four years, with 25% vesting after one year and the remainder in 36 equal monthly installments, contingent on continued employment. CAMP4 focuses on developing RNA-targeting therapeutics aimed at increasing gene expression to treat various genetic disorders by using its proprietary RAP Platform to target regulatory RNAs associated with such conditions.
Potential Positives
- The granting of stock options to new employees indicates the company's commitment to attracting and retaining talent, which is crucial for its growth and development in the competitive biopharmaceutical industry.
- The stock options have been issued according to Nasdaq Listing Rule 5635(c)(4), demonstrating the company's adherence to regulatory requirements and governance standards.
- The vesting schedule of the stock options encourages employee longevity and commitment to the company, which could enhance workforce stability and productivity.
- CAMP4 is focusing on an innovative approach to treating genetic diseases, highlighting its potential to make significant advancements in healthcare and potentially tap into a large market of over 1,200 disorders.
Potential Negatives
- The issuance of stock options to new employees may raise concerns among investors regarding the company's valuation and stock performance, especially if the company has not yet achieved significant milestones or profitability.
- Granting stock options as inducements for new hires could indicate a challenging recruitment environment, suggesting difficulties in attracting talent without such incentives.
FAQ
What is CAMP4 Therapeutics Corporation known for?
CAMP4 Therapeutics is focused on developing RNA-targeting therapeutics to treat genetic diseases by restoring healthy protein levels.
What recent stock options were granted by CAMP4?
On December 11, 2025, CAMP4's Board granted non-qualified stock options for 92,000 shares to four new employees as inducement to join.
What is the exercise price of CAMP4's stock options?
The exercise price for the stock options is $6.01, matching the closing price of CAMP4's common stock on the grant date.
How do the stock options vest at CAMP4?
The stock options vest over four years, with 25% vesting after one year, then 36 equal monthly installments contingent on service.
What is the goal of CAMP4's RAP Platform®?
The RAP Platform® aims to amplify mRNA by targeting regulatory RNAs, potentially treating over 1,200 genetic disorders with increased protein expression.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CAMP Insider Trading Activity
$CAMP insiders have traded $CAMP stock on the open market 9 times in the past 6 months. Of those trades, 9 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CAMP stock by insiders over the last 6 months:
- PARTNERS VI, LLC 5AM purchased 2,941,176 shares for an estimated $4,499,999
- AMIR NASHAT has made 2 purchases buying 1,307,189 shares for an estimated $1,999,999 and 0 sales.
- MANAGEMENT CO. VII, L.L.C. POLARIS has made 2 purchases buying 1,307,189 shares for an estimated $1,999,999 and 0 sales.
- RICHARD A YOUNG purchased 15,151 shares for an estimated $24,999
- YURI MARICICH (Chief Medical Officer) purchased 6,060 shares for an estimated $9,999
- JOSH MANDEL-BREHM (Chief Executive Officer) purchased 6,060 shares for an estimated $9,999
- KELLY GOLD (Chief Financial Officer) purchased 6,060 shares for an estimated $9,999
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CAMP Hedge Fund Activity
We have seen 12 institutional investors add shares of $CAMP stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 4,640,970 shares (+inf%) to their portfolio in Q3 2025, for an estimated $13,922,910
- VIVO CAPITAL, LLC added 3,921,568 shares (+inf%) to their portfolio in Q3 2025, for an estimated $11,764,704
- 5AM VENTURE MANAGEMENT, LLC added 2,941,176 shares (+100.5%) to their portfolio in Q3 2025, for an estimated $8,823,528
- FMR LLC added 2,415,488 shares (+397.3%) to their portfolio in Q3 2025, for an estimated $7,246,464
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,960,784 shares (+inf%) to their portfolio in Q3 2025, for an estimated $5,882,352
- SILVERARC CAPITAL MANAGEMENT, LLC added 653,594 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,960,782
- FRANKLIN RESOURCES INC removed 635,054 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $920,828
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CAMP Analyst Ratings
Wall Street analysts have issued reports on $CAMP in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 10/02/2025
- Piper Sandler issued a "Overweight" rating on 09/15/2025
To track analyst ratings and price targets for $CAMP, check out Quiver Quantitative's $CAMP forecast page.
$CAMP Price Targets
Multiple analysts have issued price targets for $CAMP recently. We have seen 2 analysts offer price targets for $CAMP in the last 6 months, with a median target of $9.5.
Here are some recent targets:
- Steve Seedhouse from Cantor Fitzgerald set a target price of $7.0 on 10/02/2025
- Edward Tenthoff from Piper Sandler set a target price of $12.0 on 09/15/2025
Full Release
CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on December 11, 2025 (the “Grant Date”), the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 92,000 shares of the Company’s common stock to four newly hired employees of the Company, each as an inducement material to each employee’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).
The Inducement Grants each have a ten-year term and an exercise price per share of $6.01, which is equal to the closing price of CAMP4’s common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee’s first day of employment with the Company, and thereafter the remainder of the option will vest in 36 equal monthly installments, subject to the employee’s continued service with CAMP4 through the applicable vesting dates. Each Inducement Grant was granted pursuant to, and is subject to, the terms and conditions of an Inducement Option Award Agreement.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (regRNAs), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. For more information, visit camp4tx.com.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
[email protected]
Media:
Jason Braco, Ph.D.
LifeSci Communications
[email protected]
